^
Association details:
| Biomarker: | TNFRSF8 positive |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3060 Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin
Published date:
11/02/2023
Excerpt:
Despite the presence of BV-refractory disease, 4 cycles of BV and nivolumab is tolerable and associated with encouraging efficacy in patients with heavily treated CD30+ lymphoma.
Trial ID:
